EyePoint (EYPT) vs Larimar Therapeutics (LRMR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Larimar Therapeutics (LRMR) has outperformed EyePoint (EYPT) over the past year, losing 41.7% versus a loss of 74.9%. Over five years, EYPT leads with a -71.0% price change compared with -77.3% for LRMR. Larimar Therapeutics is the larger company by market cap ($285.7 million vs $278.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EYPT | LRMR |
|---|---|---|
| Share price | $3.32 | $2.75 |
| Market cap | $278.35M | $285.68M |
| 1-day change | +4.73% | -1.08% |
| YTD return | -81.83% | -27.82% |
| 1-year return | -74.94% | -41.74% |
| 5-year return | -70.98% | -77.31% |
| EPS (TTM) | $-3.75 | $-1.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.11 | $6.42 |
| 52-week low | $3.05 | $2.72 |
| Distance from 52-week high | -82.63% | -57.17% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +680.42% | +423.64% |
| Average volume | 3.95M | 1.32M |
| Shares outstanding | 83.84M | 103.88M |
| Employees | 214 | 71 |
| Sector | Industrials | Health Care |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LRMR has outperformed EYPT by 33.2 percentage points over the past year.
- The two companies sit in different sectors: EyePoint in Industrials and Larimar Therapeutics in Health Care.
About EyePoint
EYPT stock →EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
Industrials · Biotechnology: Laboratory Analytical Instruments · 214 employees
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees
EYPT vs LRMR FAQ
Which is bigger, EyePoint or Larimar Therapeutics?
Larimar Therapeutics (LRMR) is larger, with a market capitalization of $285.68M compared with $278.35M for EyePoint (EYPT).
Which stock has performed better over the past year, EYPT or LRMR?
LRMR returned -41.74% over the past 12 months, compared with -74.94% for EYPT (price return, excluding dividends). Past performance does not predict future results.
Are EyePoint and Larimar Therapeutics in the same industry?
No. EyePoint is in the Industrials sector, while Larimar Therapeutics is in Health Care.